Makhlouf NA, et al. - Researchers examined the efficacy of ledipasvir/sofosbuvir for chronic hepatitis C virus (HCV) genotype 4 in adolescents with/without hematological disorders. Further, they assessed how sustained virological response (SVR) affects liver stiffness. They grouped 65 recruited adolescents into 3 patient groups: group 1, 44 treatment-naive without hematological disorders; group 2, 6 previously treated; and group 3, 15 treatment-naive with hematological disorders. Measurement of serum HCV RNA levels was done before treatment, at week 12, and at 12 weeks following the end of treatment (SVR12). With SVR12 of 100%, this work supports the efficacy of the treatment of chronic HCV in adolescents using ledipasvir/sofosbuvir. All groups exhibited significant improvement in liver stiffness.